16 research outputs found
The Use of Lithium Carbonate in the Preparation for Definitive Therapy in Hyperthyroid Patients
Efficacy of radioactive iodine treatment of gravesâ hyperthyroidism using a single calculated 131I dose
Fatores associados com recidiva precoce do hipertireoidismo apĂłs tratamento com radioiodoterapia
The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level
Outcome of radioiodine therapy without, on or 3Â days off carbimazole: a prospective interventional three-group comparison
Mudanças evolutivas no tratamento da doença de Graves com iodo radioativo: 12 anos de experiĂȘncia em um hospital universitĂĄrio Changing trends in the treatment of Graves' disease with radioiodine: a 12-year experience in a university hospital
OBJETIVO: Avaliar a mudança no perfil e abordagem dos pacientes com doença de Graves submetidos a dose terapĂȘutica de radioiodo. MATERIAIS E MĂTODOS: Avaliamos, retrospectivamente, 226 pacientes portadores de doença de Graves submetidos a dose terapĂȘutica de radioiodo entre janeiro de 1990 e dezembro de 2001. O perĂodo de 12 anos foi dividido em trĂȘs perĂodos de 4 anos para fins de anĂĄlise estatĂstica, sendo comparadas variĂĄveis clĂnicas e laboratoriais nos perĂodos descritos. RESULTADOS: Constatamos que o nĂșmero de pacientes encaminhados para a dose terapĂȘutica, assim como o percentual de pacientes do sexo feminino (de 62% para 86%; p = 0,005), tiveram incremento significativo. Houve aumento significativo no percentual de pacientes em uso de metimazol previamente Ă dose terapĂȘutica (de 9,1% para 35,6%; p = 0,03). A dose mĂ©dia de iodo administrada tambĂ©m teve incremento significativo (de 7,6 mCi para 12,7 mCi; p = 0,000003), com reflexo direto em um maior percentual de pacientes curados (de 55,6% para 83,7%; p = 0,004) um ano pĂłs-dose terapĂȘutica. CONCLUSĂO: A dose terapĂȘutica de radioiodo tem sido um mĂ©todo cada vez mais aceito nos pacientes com doença de Graves e a dose administrada tem sido cada vez maior, no intuito de cura permanente e diminuição das chances de recidiva.<br>OBJECTIVE: To evaluate the changes in clinical parameters and in the approach to patients submitted to radioiodine therapy for Graves' disease. MATERIALS AND METHODS: Dossiers of 226 patients submitted to radioiodine therapy for Graves' disease in the period between January 1990 and December 2001 were retrospectively evaluated. For the purposes of statistical analysis, the 12-year period was subdivided into three periods of 4 years, with a comparison of clinical and laboratory variables in these periods. RESULTS: The authors have observed that the total number of patients referred for radioiodine therapy as well as the percentage of female patients presented a significant increase (from 62% to 86%; p = 0.005). The percentage of patients pretreated with methimazole before radioiodine therapy increased significantly (from 9.1% to 35.6%; p = 0.03). The mean radioiodine dose delivered has also presented a significant increase (from 7.6 mCi to 12.7 mCi; p = 0.000003) with a direct reflection on a higher percentage of patients cured one year after the radioiodine therapy (from 55.6% to 83.7%; p = 0.004). CONCLUSION: Radioiodine therapy has increasingly been accepted for treatment of patients with Graves' disease and the doses delivered have increased to achieve a permanent cure as well as a reduction of the chances of recurrence